Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.58 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | BCL2 | P10415 | 2/20 | 0.51 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.51 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.48 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.48 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700190 | 0.92 | VEGFA (0.51) | VEGFAEGLN1HTR7ALDH1A1MEN1 | |
| SCHEMBL30420918 | 0.91 | HTR7 (0.53) | VEGFAEGLN1HTR7ALDH1A1CHRM2 | |
| SCHEMBL2475088 | 0.91 | HTR7 (0.53) | VEGFAEGLN1HTR7ALDH1A1CHRM2 | |
| SCHEMBL1955117 | 0.89 | MEN1 (0.49) | VEGFAEGLN1HTR7MEN1KMT2A | |
| SCHEMBL1956172 | 0.86 | VEGFA (0.57) | VEGFAEGLN1HTR7MEN1KMT2A | |
| SCHEMBL30790561 | 0.84 | VEGFA (0.51) | VEGFAEGLN1ALDH1A1MEN1KMT2A | |
| SCHEMBL32667573 | 0.84 | VEGFA (0.51) | VEGFAEGLN1ALDH1A1MEN1KMT2A | |
| SCHEMBL1741542 | 0.84 | VEGFA (0.52) | VEGFAEGLN1ALDH1A1MEN1KMT2A | |
| SCHEMBL588470 | 0.83 | ALDH1A1 (0.53) | HTR7ALDH1A1BCL2BAK1KDM4E | |
| SCHEMBL32667348 | 0.83 | VEGFA (0.64) | VEGFAEGLN1MEN1KMT2ASETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| EP-4218731-A2 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1236722-B1 | Optically active 4-(tert-butoxycarbonyl) piperazine compound, and method for producing the same | SUMITOMO CHEMICAL CO (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| US-6803465-B2 | INTERMEDIATES FOR THE PRODUCTION OF ANTIALLERGIC PHARMACEUTICALS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-10-12 | — | — | US | disclosed |
| US-20020128275-A1 | Optically active 4-(tert-butoxycarbonyl)piperazine compound, and method for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-09-12 | — | — | US | disclosed |
| EP-1236722-A1 | Optically active 4-(tert-butoxycarbonyl) piperazine compound, and method for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | VEGFA 3686/4885EGLN1 841/4885HTR7 3969/4885 |
| US-20020128275-A1 | Optically active 4-(tert-butoxycarbonyl)piperazine compound, and method for producing the same | TERT, TTI1, TBC1D15 | VEGFA 4846/4885EGLN1 817/4885HTR7 2163/4885 |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | VEGFA 3920/4885EGLN1 1532/4885HTR7 4257/4885 |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | VEGFA 3920/4885EGLN1 1532/4885HTR7 4257/4885 |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | VEGFA 3340/4885EGLN1 375/4885HTR7 1936/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | VEGFA 3920/4885EGLN1 1532/4885HTR7 4257/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | VEGFA 284/4885EGLN1 3177/4885HTR7 4492/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | VEGFA 3340/4885EGLN1 375/4885HTR7 1936/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | VEGFA 3920/4885EGLN1 1532/4885HTR7 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.